ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2923

Clinical Subsets in Giant Cell Arteritis

K Bates Gribbons1, Cristina Ponte 2, Anthea Craven 3, Joanna Robson 4, Ravi Suppiah 5, Richard Watts 6, Raashid Luqmani 3, Peter Merkel 7 and Peter C. Grayson 8, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, 3University of Oxford, Oxford, United Kingdom, 4Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, 5Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 6Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 7University of Pennsylvania, Philadelphia, PA, 8National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis, Imaging, large vessel vasculitis and biopsy, Temporal arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 13, 2019

Title: 6W024: Vasculitis – Non-ANCA-Associated & Related Disorders III: Large Vessel Vasculitis Pathogenesis & Imaging (2918–2923)

Session Type: ACR Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Giant cell arteritis (GCA) is a clinically heterogeneous disease.  Disease subsets based upon cranial versus extracranial artery involvement have been proposed.  The study objective was to determine if GCA subsets are associated with distinct clinical profiles or merely reflective of differential diagnostic assessment.

Methods: Patients were included from a large international cohort with standardized data collection.  Patients with a confirmed diagnosis of GCA were divided into four subsets based on a temporal artery (TA) abnormality [definite vasculitis by biopsy (TAB) or halo-sign positive ultrasound (TA-US)] and/or imaging evidence of large-vessel (LV, aorta and/or its primary branches) involvement on imaging: 1) patients with evidence of both LV involvement and TA abnormality (TA(+)/LV(+) GCA); 2) patients with TA abnormality without LV involvement (TA(+)/LV(-) GCA); 3) patients with LV involvement without TA abnormality (TA(-)/LV(+) GCA); and 4) patients with a clinical diagnosis of GCA without LV involvement or TA abnormality (TA(-)/LV(-) GCA).

Results: Out of 941 patients, 329 (35%) had TA-US, 705 (75%) had TAB, 536 (57%) had LV imaging, and 431 (46%) had both LV imaging and TA-US/TAB.  GCA subsets had distinct clinical profiles (Figure).  TA(+)/LV(-) GCA (n=480) had the highest burden of visual changes (e.g. amaurosis fugax, sudden ongoing visual loss; p< 0.01), other cranial ischemic symptoms (e.g. jaw claudication, scalp tenderness; p< 0.01), and TA abnormalities on physical examination (p< 0.01), with little evidence of other vascular exam abnormalities.  Patients with TA(-)/LV(-) GCA (n= 245) were nearly indistinguishable from TA(+)/LV(-) GCA with a high prevalence of visual changes and other cranial ischemic symptoms (p< 0.01) but also had a high burden of musculoskeletal symptoms (p=0.02).  Patients with TA(-)/LV(+) GCA (n=116) were younger (p< 0.01) and more frequently female (p< 0.01), with a lower burden of visual changes (p< 0.01) and cranial ischemic symptoms (p< 0.01), and a higher burden of vascular abnormalities (e.g. upper/lower limb claudication/pulse abnormality, arterial bruit, blood pressure differences; p< 0.01), constitutional (e.g. weight loss, night sweats; p< 0.01), and pulmonary symptoms (e.g. non-productive cough, dyspnea; p< 0.01).  Patients with TA(+)/LV(+) GCA (n=100) were older and more likely to be male with a high prevalence of cranial ischemic symptoms like TA(+)/LV(-) GCA and a high prevalence of lower-limb vascular abnormalities and constitutional symptoms like TA(-)/LV(+) GCA.  Patients with TA(+)/LV(+) GCA also had the highest prevalence of lab abnormalities (p< 0.01).  When analyses were restricted to 431 patients who had both TA assessment (TAB or TA-US) and LV assessment by imaging, the four subsets had similar patterns of clinical associations.

Conclusion: Patients with GCA can be divided into subsets based on temporal and extracranial artery involvement.  Each subset has a unique clinical profile that is not explained by differences in diagnostic assessment.  Longitudinal studies comparing immunologic differences and clinical outcomes across these subsets are warranted.

Clinical and demographic associations of patients with giant cell arteritis -GCA-. Patients with TA—/LV— have a clinical diagnosis of GCA without evidence of temporal artery -TA- or large vessel -LV- involvement. Patients with TA-+-/LV— have evidence of TA involvement without evidence of LV involvement on imaging. Patients with TA-+-/LV-+- have evidence of both TA involvement and LV involvement on imaging. Patients with TA—/LV-+- have evidence of LV involvement on imaging without evidence of TA involvement.


Disclosure: K. Gribbons, None; C. Ponte, None; A. Craven, None; J. Robson, None; R. Suppiah, None; R. Watts, None; R. Luqmani, Roche, 8, Roche, Vifor, InflaRx, 2; P. Merkel, AbbVie, 5, AstraZeneca, 2, 5, Biogen, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, Celgene, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 5, Genentech/Roche, 2, 5, Genetech/Roche, 2, 5, Genzyme/Sanofi, 5, GlaxoSmithKline, 2, 5, InflaRx, 5, Insmed, 5, Jannsen, 5, Kiniksa, 5, Kypha, 2, TerumoBCT, 2, UpToDate, 7; P. Grayson, None.

To cite this abstract in AMA style:

Gribbons K, Ponte C, Craven A, Robson J, Suppiah R, Watts R, Luqmani R, Merkel P, Grayson P. Clinical Subsets in Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-subsets-in-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-subsets-in-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology